Drugs / anti-HER2 CAR-M cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06224738 | Mar 2024 → Mar 2025 | gastric cancer | First People's Hospital of Hangzhou | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-HER2 CAR-M cells | “The human anti-HER2 chimeric antigen receptor macrophages (anti-HER2 CAR-M cells) independently developed use adenoviral vector system to genetically engineer autologous...” NCT06224738 ↗ |
| Action | Deplete | “which specifically bind to the human HER2 antigen to recognize and kill tumor cells” NCT06224738 ↗ |
| Modality | Cell therapy | “anti-human HER2 CAR-M cells have significant anti-tumor efficacy” NCT06224738 ↗ |